ArticlePsychopharmacology2026
Sex differences in stress responding in a randomized, placebo-controlled clinical trial of progesterone in cannabis use disorder.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleStress is a major contributor to relapse in individuals with cannabis use disorder (CUD). Stress responding in individuals with CUD differs by sex, suggesting a potential role for sex hormones in stress modulation and relapse prevention. The hormones progesterone and its precursor, pregnanolone, have been shown to attenuate the rewarding effects of cannabinoids, cocaine, and nicotine and curb stress-induced craving for cocaine, with evidence for greater effects in females.
objectivesThe present randomized controlled trial was designed to examine the impact of exogenous progesterone on stress response and cannabis use in non-treatment-seeking males and females with CUD.
methodsParticipants (n = 148; 82 males, 66 females) were randomized to receive twice daily progesterone 200 mg (n = 75) or placebo (n = 73) for one week while maintaining abstinence from cannabis. At end-of-treatment, participants were exposed to a laboratory stressor (Trier Social Stress Test), followed by a two-week medication-free follow-up period.
resultsProgesterone attenuated cannabis craving in females, but not males, and normalized relationships between subjective stress and cortisol in females and between stress and craving in both sexes. Stress-induced changes in cortisol were positively associated with time to first use during follow-up and were negatively associated with cannabis use days in the whole sample.
conclusionsResults suggest a potential role for progesterone in attenuating stress-induced relapse in CUD, particularly in females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.